Valves, Neurovascular, Diabetes Highlight Medtronic’s Fiscal 2016 Performance
This article was originally published in Clinica
Medtronic is declaring its first full year since merging with Covidien a success, with continued mid-single digit revenue growth and $355m in integration synergies, the company announced May 31.
You may also be interested in...
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.
Medtronic Misses Mid-Year Mark With 'Disappointing' 3% Growth
The medtech giant says slow sales in its cardiovascular and diabetes businesses while it awaits important product approvals were a drag on its overall revenues during the second fiscal quarter of 2017.
OUS Approvals Analysis: Summer Brings Slowdown In CE Marks
Medtech Insight’s new Approvals Tracker recorded 18 approvals outside the US, including five in vitro diagnostic approvals and five cardiovascular device approvals.